Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYBB | P04839 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19897545 | 0.84 | KDM4E (0.44) | HTR1BLMNAHTR1DL3MBTL1HTR7 | |
| SCHEMBL30395792 | 0.84 | HTR1B (0.45) | HTR1BLMNAHTR1DL3MBTL1HTR7 | |
| SCHEMBL19897869 | 0.81 | LTA4H (0.55) | LMNAL3MBTL1KDM4E | |
| SCHEMBL10678598 | 0.81 | HTR1B (0.45) | HTR1BLMNAL3MBTL1HTR7TP53 | |
| SCHEMBL19897663 | 0.77 | KDM4E (0.38) | HTR1BLMNAHTR1DL3MBTL1HTR7 | |
| SCHEMBL19911753 | 0.77 | KDM4E (0.38) | HTR1BLMNAHTR1DL3MBTL1HTR7 | |
| SCHEMBL19911752 | 0.75 | HTR1B (0.41) | HTR1BLMNAHTR1DL3MBTL1HTR7 | |
| SCHEMBL8290815 | 0.75 | L3MBTL1 (0.53) | HTR1BLMNAHTR1DL3MBTL1CYBB | |
| SCHEMBL29615262 | 0.75 | HTR1B (0.41) | HTR1BLMNAHTR1DL3MBTL1HTR7 | |
| SCHEMBL10677366 | 0.75 | HTR1B (0.44) | HTR1BLMNAL3MBTL1TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144706-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144706-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | HTR1B 4346/4885LMNA 4791/4885HTR1D 4728/4885 |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | HTR1B 4346/4885LMNA 4791/4885HTR1D 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.